PecFent is indicated for the treatment of breakthrough pain in adults who are already receiving maintenance opioid therapy for chronic cancer pain.
According to Archimedes Pharma, the SMC’s acceptence for the use of PecFent in the Scotland is based on SMC’s clinical effectiveness and health economic review of the product.
In two randomised, controlled, double blind, Phase 3 clinical trials, PecFent has showed evidence of onset of pain relief as early as 5 minutes, as well as clinically meaningful pain relief from 10 minutes.
Archimedes Pharma president and CEO Jeffrey Buchalter said the SMC’s balanced review of PecFent’s clinical effectiveness and health economic value supports Archimedes’ belief that PecFent provides a real opportunity for patients, for healthcare professionals, and for payors to improve the management of breakthrough cancer pain and the cost effectiveness of that management.